Shots:
The company initiated the patients dosing in the P-III (LIGHTHOUSE) study to evaluate the efficacy and safety profile of BIIB122 vs PBO in ~400 patients with Parkinson’s disease and a confirmed pathogenic mutation in the LRRK2 gene. The therapy is being co-develop and co-commercialized by Denali and Biogen
The 1EPs of the study are a time to confirm worsening as assessed by using MDS-UPDRS over the treatment period for ~180wks.
BIIB122 is a selective, CNS-penetrant small molecule inhibitor of LRRK2 that improves lysosomal dysfunction. BIIB122 is intended to affect the underlying biology and reduce the progression of Parkinson’s disease
Ref: Biogen | Image: Biogen
